medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 2

<< Back Next >>

Ann Hepatol 2015; 14 (2)

Fibro-check: a combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis C patients

Attallah AM, El-Far M, Abdel MCA, Omran MM, Farid K, Hussien MA, Albannan MS, Attallah AA, Elbendary MS, Elbesh DA, Elmenier NA, Abdallah MO

Language: English
References: 33
Page: 225-233
PDF size: 155.02 Kb.


ABSTRACT

Background and rationale for the study. The assessment of liver fibrosis provides useful information not only for diagnosis but also for therapeutic decision. This study was concerned with determining the levels of collagen III and its degrading enzyme matrix metalloproteinase-1 (MMP-1) as direct and complementary markers for liver fibrosis staging. Results. A total of 269 chronic hepatitis C patients constituted this study. Western blotting was used for identifying collagen III and MMP-1 in serum samples. As a result, collagen III and MMP-1 were identified, respectively, at 70 and 245 kDa using their respective mono-specific antibodies. These two markers were quantified in sera of patients using ELISA. Next, Fibro-check was constructed combining collagen III and MMP-1 together with other indirect markers which reflect alteration in hepatic functions that proved useful to stage liver fibrosis. Fibro-check produced area under the receiver-operating characteristic curve (AUC) 0.91 and 0.83 for significant (F2-F4) and cirrhosis (F4), respectively. Additionally, we estimated the performance of Fibro-check in comparison with aspartate to platelet ratio index (APRI) and fibrosis index. Fibro-check seems to be more efficient than both of them. Fibro-check was then applied to the validation study to test its accuracy and reproducibility showing AUCs 0.90 for F2-F4 and 0.86 for F4. Conclusions. Fibro-check combining ‘direct’ and ‘indirect’ markers using a mathematical formula may improve the staging of liver fibrosis with a high degree of accuracy and seems more efficient than APRI and Fibrosis index in this group of Egyptian patients.


REFERENCES

  1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.

  2. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 401-12.

  3. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, et al. Performance of the aspartate aminotransferaseto- platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatol 2011; 53: 726-36.

  4. Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatol 2011; 53: 325-35.

  5. Grigorescu M. Noninvasive Biochemical Markers of Liver Fibrosis. J Gastrointestin Liver Dis 2006; 15: 149-59.

  6. Patrick M, Asselah T, Boyer N. Fibrosis and Disease Progression in Hepatitis C. Hepatology 2002; 36: S47-S56.

  7. Jarcuška P, Janicko M, Veselíny E, Jarcuska P, Skladaný L. Circulating markers of liver fibrosis progression. Clin Chim Acta 2010; 411: 1009-17.

  8. Arthur MJP. Collagenases and liver fibrosis. J Hepatol 1995; 22: 43-8.

  9. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatol 2003; 38: 518-26.

  10. Ohta T, Sakaguchi K, Fujiwara A, Fujioka S, Iwasaki Y, Makino Y, Araki Y, et al. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama 2006; 60: 77-84.

  11. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.

  12. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.

  13. Towbin H, Stachlin T, Gordou J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.

  14. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with folinphenol reagent. J Biol Chem 1951; 193: 265-75.

  15. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiol 1983; 148: 839-43.

  16. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatol 2002; 36: S57-S64.

  17. Ladero JM. Noninvasive evaluation of liver fibrosis in patients with chronic hepatitis C. Hepat Mon 2011; 11: 698-700.

  18. Di Lullo GA, Sweeney SM, Korkko J, Ala-Kokko L, San Antonio JD. Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen. J Biol Chem 2002; 277: 4223-31.

  19. Alcolado R, Arthur MJ, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci 1997; 92: 103-12.

  20. Arthur MJ. Degradation of Matrix Proteins in Liver Fibrosis. Pathol Res Pract 1994; 190: 825-33.

  21. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.

  22. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol Mech Dis 2011; 6: 425-56.

  23. Lichtinghagen R, Bahr MJ, Wehmeier M, Michels D, Haberkorn CI, Arndt B, Flemming P, et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci 2003; 105: 373-82.

  24. Myres RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T; MULTIVIRC Group. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003; 48: 271-8.

  25. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gasteroenterol 2010; 138: 136-46.

  26. Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, Kato N, et al. Platelet count reflects stage of chronic hepatitis C. Hepatol Res 1999; 15: 192-200.

  27. Hsieh YY, Tung SY, Lee IL, Lee K, Shen CH, Wei KL, Chang TS, et al. FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis. Chang Gung Med J 2009; 32: 614-22.

  28. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterol 1988; 95: 734-9.

  29. Stauber RE, Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007; 13: 4287-94.

  30. Chu CW, Hwang SJ, Luo JC, et al. Clinical, virologic and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001; 32: 240-4.

  31. Booth JC, O’Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001; 49: 11-21.

  32. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.

  33. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.




2020     |     www.medigraphic.com